Negative in Ames, in vitro human lymphocyte chromosome aberration and in vivo rat bone marrow micronucleus assays
“Infigratinib was not mutagenic in the bacterial reverse mutation test. Infigratinib was not clastogenic in an in vitro human peripheral blood lymphocyte chromosome aberration assay or an in vivo bone marrow micronucleus assay in rats.”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗
Carcinogenicity
Not conducted (advanced cancer indication)
“Carcinogenicity studies are not recommended for the proposed indication.”
✓ VerifiedFDA multi-discipline review, p. 67Source ↗
Reproductive & developmental
Rat EFD: embryofetal death at 10 mg/kg/day, reduced fetal weight at ≥3 mg/kg/day, fetal abnormalities at all doses
“Increases in embryo‐fetal death, with corresponding reductions in the numbers of viable fetuses, were observed at 10 mg/kg/day, and reductions in mean fetal body weights were observed at 3 and 10 mg/kg/day. Fetal abnormalities were observed at increased incidences at all doses.”
✓ VerifiedFDA multi-discipline review, p. 67Source ↗
Safety pharmacology
No significant cardiovascular effects in telemetered dogs; no neurobehavioral or respiratory effects in rats
“Infigratinib had no toxicologically significant effects on cardiovascular function in telemetered dogs or on neurobehavioral and respiratory functions in rats.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative